Blueprint Medicines Corp (NASDAQ: BPMC) has reported a loss for its fourth fiscal quarter (ending December 31) of $-0.79 versus a loss $-1.82 for the same period a year ago. Relative to the consensus estimate of $-0.73, this was a shortfall of $-0.06. For the latest four quarters through December 31, E.P.S. were $-1.07 versus $-8.37 for the same period a year ago.
Recent Price Action
Blueprint Medicines Corp (NASDAQ: BPMC) stock suffered a large decline of -8.1% on 2/13/25. The stock closed at $95.19. Moreover, exceptionally high trading volume at 309% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months and has declined -13.8% during the last week.
Current PriceTarget Research Rating
Blueprint Medicines has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Blueprint Medicines has a poor Power Rating of 19 and a very low Appreciation Score of 1, producing the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment